Pfizer

Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have...

Johnson and Johnson

Johnson & Johnson is a leading pharmaceutical and healthcare company, with annual sales in 2009 of $22,520 million, ranking it the 8th largest pharmaceutical company in the world (based on sales...

Seroquel

Seroquel, an atypical antipsychotic medication has annual sales of $3.1m (in 2009), and based on annual sales, ranks 5th in the world. It is produced by AstraZeneca Pharmaceuticals as a quetiapine f...

Abilify

Abilify (Aripiprazole) is an atypical antipsychotic produced by Bristol-Myers Squibb Company, with annual sales of $3m, ranking it 6th in the world for annual sales.  Abilify is prescribed in...

Staphylococcal aureus infections

Staphylococcal aureus infections represent an enormous burden to public health systems. Traditionally restricted to the hospital setting as nosocomial infections, highly virulent strains have recently...

TEXT-S&P assigns Rottapharm preliminary 'BB-' rating; outlook stable

-- Italy-based health care group Rottapharm SpA (Rottapharm) is to raise EUR400 million of senior unsecured notes to refinance its upcoming debt maturities.

TEXT - Fitch rates Rottapharm SpA

(The following statement was released by the rating agency) Overview -- Italy-based health care group Rottapharm has raised EUR400 million of senior unsecured notes to refinance its upcoming d...

Rottapharm halts talks with Clessidra, Avista

MILAN, July 25 (Reuters) - Italy's Rovati family said on Wednesday it had decided to halt talks to sell 50 percent of pharmaceutical group Rottapharm-Madaus to private equity firms Avista and Clessidr...

Clessidra, Avista reach deal to buy 50 pct of Rottapharm-source

MILAN, July 9 (Reuters) - Private equity firms Clessidra Capital Partners and Avista Capital Partners have reached an agreement to buy 50 percent of family-owned Italian pharmaceutical group Rottapha...

BRIEF-Moody's assigns (P)B1 CFR to Rottapharm; outlook stable

* Moody's assigned a provisional (P)B1 corporate family rating (CFR) and a provisional (P)B1 probability of default rating (PDR) to Rottapharm SpA. At the same time, Moody's has assigned a provisional...

Antitope, Rottapharm Madaus deal

Vitrolife AB (publ): Annual report 2012

Regulatory News: Today Vitrolife (STO:VITR) is publishing the Annual Report for 2012 in Swedish. The Annual Report is attached to this press release and will also be available on www.vitrolife.com...

Diamyd Medical: Annual Report 11/12

Regulatory News: Diamyd Medical (STO:DIAMB)(Pink Sheets:DMYDY): The Diamyd Medical Annual Report for 2011/2012 is now available in English. The annual rep...

Systematic Review: Annual Incidence of ACL Injury and Surgery in Various Populations.

Accurate documentation of injury incidence is critical for study of injury risk factors and prevention. Comparisons of published incidences of anterior cruciate ligament (ACL) injuries and surgical re...

Adenocarcinoma in Barrett's Esophagus.

To the Editor: In their population-based cohort study, Hvid-Jensen et al. (Oct. 13 issue)(1) report an annual risk of esophageal adenocarcinoma of 0.12% among patients with Barrett's esophagus. This a...

Adenocarcinoma in Barrett's Esophagus.

To the Editor: In their population-based cohort study, Hvid-Jensen et al. (Oct. 13 issue)(1) report an annual risk of esophageal adenocarcinoma of 0.12% among patients with Barrett's esophagus. This a...

New aspects of polytrauma treatment - current facts and developments : Report of the first annual conference of the Committee on Emergency Medicine, Intensive Care and Trauma Management (Sektion NIS).

Taking care of severely injured patients is a complex and ambitious mission. The committee on emergency medicine, intensive care and trauma management of the German Society of Trauma Surgery (Sektion...

Annual Review of Physical Chemistry, Vol. 61 Annual Review of Physical Chemistry, Vol. 61 . Edited by Stephen R. Leone (University of California, Berkeley), Paul S. Cremer (Texas A&M University), Jay T. Groves (University of California, Berkeley), Mark A.